Introductory rate of $355 expires 3/26/10. Save $70 off the regular rate of $425. Click the sample link below to view the complete table of contents and select pages.

The biotechnology industry was eager to leave behind 2009 and the negative effects of the global economic recession that impacted even some of the premiere biotech players. Positive notes from the past year included a record total value for partnership deals during one of the most-difficult financing environments ever, and the industry hopes to keep up that pace during 2010. The biotech corporations that survived the challenging financial climate will have to continue adapting to fast-changing surroundings.

Also acclimating to the altering business conditions is Big Pharma. Three prime-time deals were made during 2009 by pharma leaders, and each of the acquired companies possessed valuable biotech/biological product assets. Some major pharma companies are in the process of transforming their operations via a biopharmaceutical business model to remain competitive against the rapidly growing generics market. Meanwhile, Big Pharma and Big Biotech will continue to compete for smaller companies armed with advanced product pipelines and significant technologies.

2010 appears to be the year that a U.S. regulatory pathway for biosimilars/follow-on biologics is finally established. House and Senate bills are shaping the much-anticipated outcome regarding the length of patent protection for biotech drugs, which most likely will fall in the 10-to-12 year range.

Prescription-drug pipeline for the biotech industry detail the following for
each product:
• Each pipeline products’ chemical or substance composition, intended
indication, class of drug, clinical status, region of development, and the
product developer/intended marketer
• Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/
III, Phase III, and awaiting approval
• Region of development includes the United States, Europe, and Japan